Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly prescribed for weight management. Similar to the early implementation of metabolic and bariatric surgery (MBS), little is known about how GLP-1RAs affect individuals with eating disorders (EDs) or their potential to promote, mask, or exacerbate ED psychopathology. Lacking robust empirical data directly examining associations between GLP-1RAs and ED risk, we draw on lessons from the field of MBS to summarize current critical knowledge gaps and guide clinicians, educators, researchers, and advocates on interim decision-making.